[1]
Guy, D., Glicksman, R., Buckley, R., Cheung, P., Chung, H., Flax, S., Hajek, D., Loblaw, A., Morton, G., Noakes, J., Spevack, L., Chin, J.L. and Rodrigues, G. 2021. Metastatic progression following multimodal therapy for unfavorable-risk prostate cancer. Canadian Urological Association Journal. 16, 4 (Nov. 2021), E220–6. DOI:https://doi.org/10.5489/cuaj.7525.